ATTACC/ACTIV-4a/REMAP-CAP: Multiplatform, Open-Label RCT of Therapeutic Anticoagulation in Noncritically Ill, Hospitalized Patients With COVID-19 in 9 Countries1 |
Key Inclusion Criterion - Hospitalized with laboratory-confirmed SARS-CoV-2 infection without need for HFNC oxygen, NIV, MV, vasopressors, or inotropes
Key Exclusion Criteria - Hospital discharge expected in ≤72 hours
- Requirement for therapeutic anticoagulation or dual antiplatelet therapy
- High bleeding risk
Interventions - Therapeutic UFH or LMWH for 14 days or until hospital discharge, whichever came first (n = 1,190)
- SOC, which included prophylactic UFH or LMWH (n = 1,054)
Primary Endpoint - Organ support-free days at Day 21, as measured by an OS
Key Secondary Endpoints - Survival until hospital discharge
- Hospital LOS
- Thrombosis or major bleeding events
| Participant Characteristics - Median age 59 years; 59% men; median BMI 30
- 52% with HTN; 30% with DM; 11% with CVD
- 66% required low-flow oxygen
- D-dimer:
- 48.4% <2 times ULN
- 28.4% ≥2 times ULN
- 23.1% unknown
- 62% on corticosteroids; 36% on RDV
Primary Outcomes - Therapeutic anticoagulation superior to SOC for organ support-free days (aOR 1.27; 95% CrI, 1.03–1.58; 99% posterior probability)
- 4% absolute difference in survival until hospital discharge without organ support that favored therapeutic arm (95% CrI, 0.5–7.2)
- Outcome consistent across D-dimer stratum
Secondary Outcomes - Survival until hospital discharge: 92% in both arms
- No difference between arms in hospital LOS (aOR 1.03; 95% CrI, 0.94–1.13)
- Thrombosis: 1% in therapeutic arm vs. 2% in SOC arm
- Major bleeding events: 2% in therapeutic arm vs. 1% in SOC arm
| Key Limitations - Open-label study
- Anticoagulation dose varied in SOC arm (27% received intermediate-dose thromboprophylaxis)
- Varied criteria for ICU care and expected hospital LOS
- Only enrolled 17% of screened patients
Interpretation - Therapeutic heparin increased the number of organ support-free days and decreased the number of patients requiring organ support.
- Therapeutic heparin did not significantly affect hospital LOS or the number of major thrombosis events or deaths.
- Major bleeds occurred 1% more frequently in therapeutic arm than in SOC arm.
|
RAPID: Open-Label RCT of Therapeutic Heparin in Moderately Ill, Hospitalized Patients With COVID-19 in 6 Countries2 |
Key Inclusion Criteria - Hospitalized with COVID-19 and D-dimer ≥2 times ULN or any elevated D-dimer level and SpO2 ≤93% on room air
- Hospitalized <5 days
Key Exclusion Criteria - Indication for therapeutic anticoagulation
- Dual antiplatelet therapy
- High bleeding risk
Interventions - Therapeutic UFH or LMWH for 28 days or until discharge or death (n = 228)
- Prophylactic UFH or LMWH for 28 days or until discharge or death (n = 237)
Primary Endpoint - Composite of ICU admission, NIV or MV, or death up to 28 days
Key Secondary Endpoints - All-cause death
- Mean number of organ support-free days
- VTE
- Major bleeding event
- Mean number of hospital-free days alive
| Participant Characteristics - Median age 60 years; 57% men; mean BMI 30
- 48% with HTN; 34% with DM; 7% with CVD
- 91% had hypoxia; 6% received HFNC oxygen
- D-dimer:
- 49% <2 times ULN
- 51% ≥2 times ULN
- 69% on corticosteroids
Primary Outcome - Composite of ICU admission, NIV or MV, or death up to 28 days: 16% in therapeutic arm vs. 22% in prophylactic arm (OR 0.69; 95% CI, 0.43–1.10)
Secondary Outcomes - All-cause death: 2% in therapeutic arm vs. 8% in prophylactic arm (OR 0.22; 95% CI, 0.07–0.65)
- Mean number of organ support-free days: 26 in therapeutic arm vs. 24 in prophylactic arm (OR 1.41; 95% CI, 0.9–2.21)
- No difference between arms for VTE (1% in therapeutic arm vs. 3% in prophylactic arm) or major bleeding events (1% in therapeutic arm vs. 2% in prophylactic arm)
- Mean number of hospital-free days alive: 20 in therapeutic arm vs. 18 in prophylactic arm (OR 1.09; 95% CI, 0.79–1.50)
| Key Limitations - Open-label study
- Only enrolled 12% of screened patients
Interpretation - Compared to prophylactic heparin, therapeutic heparin reduced mortality (a secondary endpoint) but had no effects on the composite primary endpoint of ICU admission, the need for NIV or MV, or death up to 28 days.
- There were no differences between the arms in the percentages of patients who experienced major bleeding events or VTE.
|
HEP-COVID: Open-Label RCT of Therapeutic Heparin in High-Risk, Hospitalized Patients With COVID-19 in the United States3 |
Key Inclusion Criteria- Hospitalized with COVID-19 and required supplemental oxygen
- D-dimer >4 times ULN or sepsis-induced coagulopathy score of ≥4
- Hospitalized <72 hours
Key Exclusion Criteria - Indication for therapeutic anticoagulation
- Dual antiplatelet therapy
- High bleeding risk
- CrCl <15 mL/min
Interventions - Therapeutic LMWH until hospital discharge or primary endpoint met (n = 129)
- Usual care of prophylactic or intermediate-dose LMWH until hospital discharge or primary endpoint met (n = 124)
Primary Endpoint - Composite of VTE, ATE, or death from any cause within 32 days of randomization
Key Safety Endpoint | Participant Characteristics - Median age 67 years; 54% men; mean BMI 30
- 60% with HTN; 37% with DM; 75% with CVD
- 64% received oxygen via nasal cannula; 15% received high-flow oxygen or NIV; 5% received MV
- 80% on corticosteroids
Primary Outcomes - Composite of VTE, ATE, or death within 32 days: 29% in therapeutic arm vs. 42% in usual care arm (relative risk 0.68; 95% CI, 0.49–0.96)
- Death: 19% in therapeutic arm vs. 25% in usual care arm (relative risk 0.78; 95% CI, 0.49–1.23)
- Thrombotic events: 11% in therapeutic arm vs. 29% in usual care arm (relative risk 0.37; 95% CI, 0.21–0.66)
- Non-ICU stratum composite of VTE, ATE, or death within 32 days: 17% in therapeutic arm vs. 36% in usual care arm (relative risk 0.46; 95% CI, 0.27–0.81)
Key Safety Outcomes - Major bleeding events within 32 days: 5% in therapeutic arm vs. 2% in usual care arm (relative risk 2.88; 95% CI, 0.59–14.02)
- Non-ICU stratum major bleeding events within 32 days: 2% in both arms
| Key Limitations - Open-label study
- Only enrolled 2% of screened patients
Interpretation - Compared to usual care, therapeutic LMWH reduced the incidence of VTE, ATE, and death.
- Among patients who were not in the ICU, therapeutic LMWH significantly reduced the percentage of patients who experienced thrombotic events and did not increase the percentage of patients who experienced major bleeding events.
|
ACTION: Open-Label RCT of Therapeutic Rivaroxaban in Hospitalized Patients With COVID-19 in Brazil4 |
Key Inclusion Criteria - Hospitalized for COVID-19 with elevated D-dimer level
- Symptoms for ≤14 days
Key Exclusion Criteria - Indication for therapeutic anticoagulation
- CrCl <30 mL/min
- P2Y12 inhibitor therapy or aspirin >100 mg
- High bleeding risk
Interventions - Therapeutic anticoagulation for 30 days: rivaroxaban 15 mg or 20 mg daily; if clinically unstable, enoxaparin 1 mg/kg twice daily or UFH (n = 311)
- Usual care prophylactic anticoagulation with enoxaparin or UFH during hospitalization (n = 304)
Primary Endpoint - Hierarchical composite of time to death, hospital duration, or oxygen use duration through Day 30
Key Secondary Endpoints - Thrombosis, with and without all-cause death
- Mortality
- Bleeding events
| Participant Characteristics - Median age 57 years; 60% men; mean BMI 30
- 49% with HTN; 24% with DM; 5% with coronary disease
- Critically ill: 7% in therapeutic arm vs. 5% in usual care arm
- 75% required oxygen: 60% low-flow oxygen; 8% HFNC oxygen; 1% NIV; 6% MV
- 83% on corticosteroids
Primary Outcome - No difference between arms in the composite of time to death, hospital duration, or oxygen use duration through Day 30 (win ratio 0.86; 95% CI, 0.59–1.22)
Secondary Outcomes - No difference between therapeutic and usual care arms in:
- Thrombosis: 7% vs. 10%
- Mortality: 11% vs. 8%
- Any bleeding: 12% in therapeutic arm vs. 3% in usual care arm
- Major bleeding: 3% in therapeutic arm vs. 1% in usual care arm
- Clinically relevant, nonmajor bleeding: 5% in therapeutic arm vs. 1% in usual care arm
| Key Limitations - Open-label study
- Only enrolled 18% of screened patients
- Therapeutic rivaroxaban was administered for a longer duration than prophylactic anticoagulation (30 days vs. a mean duration of 8 days).
Interpretation - When compared with usual care, therapeutic rivaroxaban did not reduce mortality, hospital duration, oxygen use duration, or the percentage of patients who experienced thrombosis.
- Patients who received therapeutic rivaroxaban had more clinically relevant nonmajor bleeding events than those who received usual care.
- The longer duration of therapy in the rivaroxaban arm may have influenced the difference in bleeding events.
|
FREEDOM: RCT of Anticoagulation Strategies in Noncritically Ill Patients Who Were Hospitalized With COVID-19 in 10 Countries5 |
Key Inclusion Criterion - Hospitalized for symptomatic COVID-19 for <48 hours
Key Exclusion Criteria - Indication for therapeutic anticoagulation
- CrCl <30 mL/min
- P2Y12 inhibitor therapy or aspirin >100 mg per day
- Anticipated hospitalization for <72 hours
Interventions - Therapeutic apixaban 5 mg twice daily (n = 1,121)
- Therapeutic enoxaparin 1 mg/kg twice daily (n = 1,136)
- Usual care prophylactic enoxaparin (n = 1,141)
Primary Endpoint - 30-day composite of all-cause mortality, need for ICU-level care, systemic thromboembolism, or ischemic stroke. Endpoint assessed for the combined therapeutic arms vs. the prophylactic arm.
Key Secondary Endpoints - All-cause mortality
- Bleeding events (BARC type 3 or 5)
| Participant Characteristics - Median age 52 years; 59% men; mean BMI 26
- 32% with HTN; 19% with DM
- 22% on corticosteroids; 10% on RDV
Primary Outcome - 30-day composite outcome: 11.3% in combined therapeutic arms vs. 13.2% in prophylactic arm (HR 0.85; 95% CI, 0.69–1.04; P = 0.11)
- Primary endpoint was not statistically significant when therapeutic enoxaparin or apixaban were compared to prophylactic enoxaparin.
Secondary Outcomes - All-cause mortality: 4.9% in therapeutic enoxaparin arm vs. 7.0% in prophylactic enoxaparin arm (HR 0.69; 95% CI, 0.49–0.99)
- All-cause mortality: 5.0% in therapeutic apixaban arm vs. 7.0% in prophylactic enoxaparin arm (HR 0.7; 95% CI, 0.49–0.99)
- BARC type 3 or 5 bleeding: 0.4% in combined therapeutic arms vs. 0.1% in prophylactic arm (IRR 3.96; 95% CI, 0.50–31.27)
| Key Limitations - Open-label study
- Terminated early due to slow recruitment (3,452 of 3,600 planned patients recruited)
- Minimal treatment with RDV or DEX as SOC for COVID-19
Interpretation - When compared with prophylactic enoxaparin, therapeutic apixaban or therapeutic enoxaparin did not reduce 30-day mortality, the need for ICU-level care, thromboembolism, or ischemic stroke.
- Fewer patients died in the therapeutic enoxaparin and therapeutic apixaban arms than in the prophylactic enoxaparin arm.
- There were no statistically significant differences between the arms in the number of severe bleeding events.
|
COVID-PACT: Open-Label RCT of Full-Dose Versus Prophylactic-Dose Anticoagulation in Adults With COVID-19 Who Were Receiving Intensive Care Unit-Level Care in the United States6 |
Key Inclusion Criteria - Aged ≥18 years
- Acute SARS-CoV-2 infection
- ICU-level care for ≤96 hours prior to randomization
Key Exclusion Criteria - Ongoing or planned use of full-dose anticoagulation or dual antiplatelet therapy
- High risk of bleeding events
- History of HIT
- Ischemic stroke within 2 weeks
Interventions - Full-dose anticoagulation until Day 28 or hospital discharge, whichever came first (n = 197)
- Prophylactic anticoagulation (n = 193)
- Eligible patients were also randomized 1:1 to receive clopidogrel or no antiplatelet therapy (n = 292)
Primary Endpoint - Composite of VTE or ATE events, including death due to VTE or ATE, PE, clinically evident DVT, MI, ischemic stroke, systemic embolic event or acute limb ischemia, or clinically silent DVT through hospital discharge or Day 28
Key Secondary Endpoint - Individual outcomes listed above, with the exception of clinically silent DVT
Safety Endpoints - Fatal or life-threatening bleeding events
- Moderate or severe bleeding events
| Participant Characteristics - Median age 61 years; 41% women; 71% White
- 99% required HFNC oxygen, NIV, or MV; 15% required MV (41% required MV during the study)
- 31% to 37% crossed over to an alternative study treatment during the study
Primary Outcome - Composite of VTE or ATE events: 12% in full-dose anticoagulation arm vs. 6% in prophylactic anticoagulation arm (win ratio 1.95; 95% CI, 1.08–3.55; P = 0.028)
Secondary Outcome - Clinically evident VTE or ATE: 10% in full-dose anticoagulation arm vs. 6% in prophylactic anticoagulation arm (win ratio 1.79; 95% CI, 0.92–3.47; P = 0.087)
Safety Outcomes - No fatal bleeding events in either arm
- Life-threatening bleeding events: 4 (2.1%) in full-dose anticoagulation arm vs. 1 (0.5%) in prophylactic anticoagulation arm (P = 0.19)
- Moderate or severe bleeding events: 15 (7.9%) in full-dose anticoagulation arm vs. 1 (0.5%) in prophylactic anticoagulation arm (P = 0.002)
| Key Limitations - Open-label study (adjudication committee members were blinded to the study arms)
- Stopped early because the decreasing number of ICU admissions for patients with COVID-19 made recruitment difficult.
- There was an unequal crossover between the arms, with a greater crossover from the prophylactic anticoagulation arm to the full-dose anticoagulation arm.
Interpretation - Among patients with COVID-19 who required ICU-level care, patients who received full-dose anticoagulation had fewer VTE or ATE events but no survival benefit compared to those who received prophylactic anticoagulation.
- The prevalence of moderate or severe bleeding events was higher among patients who received full-dose anticoagulation than among those who received prophylactic anticoagulation.
|
REMAP-CAP/ACTIV-4a/ATTACC: Multiplatform, Open-Label RCT of Therapeutic Anticoagulation in Critically Ill, Hospitalized Patients With COVID-19 in 20 Countries7 |
Key Inclusion Criteria - Hospitalized with severe COVID-19 and receiving HFNC oxygen, NIV, MV, ECMO, vasopressors, or inotropes
- Hospitalized <72 hours (ACTIV-4a, ATTACC) or <14 days (REMAP-CAP)
Key Exclusion Criteria - Hospital discharge expected within 72 hours
- Requirement for therapeutic anticoagulation or dual antiplatelet therapy
- High bleeding risk
Interventions - Therapeutic UFH or LMWH for 14 days or until discharge, whichever came first (n = 534)
- Usual care (n = 564)
Primary Endpoint - Number of organ support-free days by Day 21
Key Secondary Endpoints - Survival to hospital discharge
- Any thrombosis
- Composite of major thrombotic events or death
- Bleeding events
| Participant Characteristics - Median age 60 years; 70% men; median BMI 30
- 24% with chronic respiratory disease; 33% with DM; 10% with chronic kidney disease; 8% with severe CVD
- 32% required HFNC oxygen; 38% required NIV; 29% required MV
- 18% on vasopressors; 82% on corticosteroids; 32% on RDV
Primary Outcome - Median number of organ support-free days by Day 21: 4 in therapeutic arm vs. 5 in usual care arm (aOR 0.83; 95% CrI, 0.67–1.03; 99.9% posterior probability of futility; OR < 1.2)
Secondary Outcomes - No difference between therapeutic and usual care arms in:
- Survival to hospital discharge: 63% vs. 65% (aOR 0.84; 95% CrI, 0.64–1.11)
- Thrombosis: 6% vs. 10%
- Major thrombotic events or death: 41% in both arms
- Major bleeding events: 4% vs. 2% (aOR 1.48; 95% CrI, 0.75–3.04)
| Key Limitations - Open-label study
- Anticoagulation dose varied in usual care arm (i.e., 51% intermediate, 2% subtherapeutic, 5% therapeutic).
- Inclusion criteria for hospital LOS and ICU-level care differed across trials.
- Trial stopped for futility.
Interpretation - In patients who required ICU-level care, therapeutic heparin did not reduce the duration of organ support or mortality.
- Although the differences were not significant, patients who received therapeutic anticoagulation had more bleeding events and fewer thrombotic events than patients who received usual care.
|
INSPIRATION: Open-Label RCT of Intermediate-Dose Versus Prophylactic-Dose Anticoagulation in Patients With COVID-19 in Intensive Care Units in Iran8 |
Key Inclusion Criteria - Admitted to ICU
- Hospitalized <7 days
Key Exclusion Criteria - Life expectancy <24 hours
- Indication for therapeutic anticoagulation
- Overt bleeding
Interventions - Intermediate-dose anticoagulation: enoxaparin 1 mg/kg once daily (n = 276)
- Prophylactic-dose anticoagulation (n = 286)
Primary Endpoint - Composite of adjudicated acute VTE, ATE, the need for ECMO, or all-cause mortality within 30 days
Key Secondary Endpoints - All-cause mortality
- VTE
- Bleeding events
| Participant Characteristics - Median age 62 years; 58% men; median BMI 27
- 44% with HTN; 28% with DM; 14% with coronary artery disease
- 32% required NIV; 20% required MV
- 23% on vasopressors; 93% on corticosteroids; 60% on RDV
Primary Outcome - Composite of adjudicated acute VTE, ATE, the need for ECMO, or all-cause mortality: 46% in therapeutic arm vs. 44% in prophylactic arm (OR 1.06; 95% CI, 0.76–1.48)
Secondary Outcomes - No difference between therapeutic and prophylactic arms in:
- All-cause mortality: 43% vs. 41%
- VTE: 3% in both arms
- Major bleeding events and clinically relevant nonmajor bleeding events: 6.3% vs. 3.1% (OR 2.02; 95% CI, 0.89–4.61)
| Key Limitations - Open-label study
- Not all patients received ICU-level care.
Interpretation - Intermediate-dose anticoagulation did not significantly reduce the occurrence of VTE and ATE, the need for ECMO, or mortality.
- Although the difference was not significant, patients who received intermediate-dose anticoagulation had more bleeding events than patients who received usual care.
|
OVID: Open-Label RCT of Low-Molecular-Weight Heparin for Thromboprophylaxis in Symptomatic, Nonhospitalized Patients With COVID-19 in Germany and Switzerland9 |
Key Inclusion Criteria - Aged ≥50 years
- Positive SARS-CoV-2 test result within past 5 days
- Respiratory symptoms or temperature ≥37.5°C
Key Exclusion Criteria - Severe renal or hepatic dysfunction
- Severe anemia or recent major bleeding
- Dual antiplatelet therapy
Interventions - Enoxaparin 40 mg SUBQ once daily for 14 days (n = 234)
- SOC (n = 238)
Primary Endpoint - Composite of any untoward hospitalization or all-cause death by Day 30
Key Secondary Endpoint - Composite of major arterial and venous cardiovascular events by Day 30
- Bleeding events
| Participant Characteristics - Median age 57 years; 46% women; 96% White
- Median time from COVID-19 diagnosis to randomization: 3 days
- 24% with HTN; 8% with DM; 5% with CVD
- 9.5% received at least 1 dose of a COVID-19 vaccine
Primary Outcome - Composite of any untoward hospitalization or all-cause death by Day 30: 8 (3%) in enoxaparin arm vs. 8 (3%) in SOC arm (adjusted relative risk 0.98; 95% CI, 0.37–2.56; P = 0.96)
Key Secondary Outcomes - Composite of major arterial and venous cardiovascular events by Day 30: 2 (1%) in enoxaparin arm vs. 4 (2%) in SOC arm (relative risk 0.51; 95% CI, 0.09–2.74)
- No major or clinically relevant nonmajor bleeding events occurred
| Key Limitations - Open-label study
- Study terminated early due to a low probability that enoxaparin would be superior to the standard of care for the primary outcome.
Interpretation - Thromboprophylaxis with enoxaparin did not reduce the risk of hospitalization or death among nonhospitalized, symptomatic patients with COVID-19.
|
ETHIC: Open-Label RCT of Low-Molecular-Weight Heparin for Thromboprophylaxis in Symptomatic Outpatients With COVID-19 in Belgium, Brazil, India, South Africa, Spain, and the UK10 |
Key Inclusion Criteria - Aged ≥30 years
- RT-PCR-confirmed SARS-CoV-2 infection, with symptoms for ≤9 days
- ≥1 risk factor for severe disease
Key Exclusion Criteria - Receipt of COVID-19 vaccination
- eGFR <30 mL/min
- Anticoagulant or antiplatelet therapy, except low-dose aspirin
Interventions - Enoxaparin 40 mg SUBQ daily (for patients weighing <100 kg) or enoxaparin 40 mg SUBQ twice daily (for patients weighing ≥100 kg), self-administered for 21 days (n = 105)
- SOC (n = 114)
Primary Endpoint - Composite of all-cause hospitalization or all-cause mortality by Day 21
Key Secondary Endpoints - VTE by Day 90
- Bleeding events by Day 50
| Participant Characteristics - Median age 59 years; 56% men
- Median time from first symptom to randomization: 5 days
Primary Outcomes - Composite of all-cause hospitalization or all-cause mortality by Day 21: 12 (11%) in enoxaparin arm vs. 12 (11%) in SOC arm (HR 1.09; 95% CI, 0.49–2.43; P = 0.83)
- Patients who required hospitalization: 12 in enoxaparin arm vs. 12 in SOC arm
- Hospitalized patients who required acute medical care or ICU admission: 4 in enoxaparin arm vs. 0 in SOC arm
Key Secondary Outcomes - VTE by Day 90: 1 (1%) in enoxaparin arm vs. 2 (2%) in SOC arm
- Bleeding events by Day 50: 2 (2%) in enoxaparin arm vs. 2 (2%) in SOC arm
| Key Limitations - Open-label study
- Study terminated early because of low event rate and lack of efficacy.
Interpretation - This study demonstrated no benefit of prophylaxis with LMWH in outpatients with COVID-19 who were at risk of progressing to severe disease.
|
ACTIV-4C: Double-Blind RCT of 30 Days of Apixaban After Hospital Discharge in Patients With COVID-19 in the United States11 |
Key Inclusion Criteria - Hospitalized >48 hours with confirmed SARS-CoV-2 infection within 2 weeks of admission
- Platelet count >50 x 109 cells/L and hemoglobin >8 g/dL
Key Exclusion Criteria - Indication for therapeutic or prophylactic anticoagulation at discharge
- Ischemic stroke, intracranial bleed, or neurosurgery within 3 months
- Bleeding within past 30 days
- Major surgery within 14 days
- Inherited or active acquired bleeding disorder
Interventions - Apixaban 2.5 mg twice daily for 30 days, starting at hospital discharge (n = 610)
- Placebo (n = 607)
Primary Endpoint - Composite of death, ATE, or VTE by Day 30
Key Safety Endpoint | Participant Characteristics - Median age 54 years; 50% men; 27% Black, 17% Hispanic
- 15% were receiving antiplatelet therapy
- At discharge, 16% were prescribed antiplatelet therapy; 93% received aspirin.
Primary Outcome - Composite of death, ATE, or VTE by Day 30: 13 (2.1%) in apixaban arm vs. 14 (2.3%) in placebo arm (relative risk 0.92; 95% CI, 0.44–1.95; P = 0.85)
Safety Outcomes - Major bleeding events: 2 (0.4%) in apixaban arm vs. 1 (0.2%) in placebo arm (relative risk 2.00; 95% CI, 0.18–22.03)
- Clinically relevant nonmajor bleeding events: 3 (0.6%) in apixaban arm vs. 6 (1.1%) in placebo arm (relative risk 0.50; 95% CI, 0.13–1.99)
| Key Limitation - Trial was terminated early due to a low event rate and because the decreasing number of hospitalizations for people with COVID-19 made recruitment difficult.
Interpretation - Incidence of death or thromboembolism was low in this cohort of patients.
- Because the trial was terminated early, the results were imprecise, and the study was inconclusive.
|
MICHELLE: Open-Label RCT of Using Rivaroxaban After Hospital Discharge in Patients With COVID-19 Who Were at High Risk of Venous Thromboembolism in Brazil12 |
Key Inclusion Criteria - Hospitalized for ≥3 days with confirmed SARS-CoV-2 infection
- Increased risk of VTE, defined as an IMPROVE VTE score at hospital discharge of >4 or 2–3 with a D-dimer level >500 ng/mL
Key Exclusion Criterion - Suspicion or confirmation of a thrombotic event
Interventions - Rivaroxaban 10 mg PO once daily for 35 days, starting at hospital discharge (n = 159)
- No anticoagulation (n = 159)
Primary Endpoint - Composite of symptomatic or fatal VTE, asymptomatic VTE on bilateral lower-limb venous ultrasound and CTPA, symptomatic ATE, or cardiovascular death by Day 35
Key Secondary Endpoints - Symptomatic or fatal VTE
- Composite of symptomatic VTE, MI, non-hemorrhagic stroke, or cardiovascular death
Key Safety Endpoint | Participant Characteristics - Median age 57 years; 60% men
- While hospitalized, 86% received thromboprophylaxis with enoxaparin, 14% received unfractionated heparin, and 5% received antiplatelet therapy.
Primary Outcomes - Primary composite outcome by Day 35: 5 (3%) in rivaroxaban arm vs. 15 (9%) in no anticoagulation arm (relative risk 0.33; 95% CI, 0.12–0.90; P = 0.03)
- Difference driven mainly by incidence of pulmonary embolism (2 in rivaroxaban arm vs. 10 in no anticoagulation arm)
Key Secondary Outcomes - Symptomatic or fatal VTE: 1 (0.6%) in rivaroxaban arm vs. 8 (5.0%) in no anticoagulation arm (relative risk 0.13; 95% CI, 0.02–0.99; P = 0.049)
- Composite of symptomatic VTE, MI, stroke, or cardiovascular death: 1 (0.6%) in rivaroxaban arm vs. 9 (5.7%) in no anticoagulation arm (relative risk 0.11; 95% CI, 0.01–0.87; P = 0.036)
Safety Outcome - No major bleeding events occurred in either arm.
| Key Limitations - Open-label study with no placebo
- Not all patients had the protocol-specified CTPA or Doppler ultrasound during the study. However, a higher number of imaging evaluations occurred among the patients in the rivaroxaban arm.
Interpretation - In patients who were at high risk of VTE, the use of thromboprophylaxis with rivaroxaban 10 mg PO once daily for 35 days improved clinical outcomes when compared with no anticoagulation.
|
|